Drug Profile


Alternative Names: DP 1904; SR 96325

Latest Information Update: 19 Dec 2000

Price : $50

At a glance

  • Originator Daiichi Pharmaceutical
  • Developer Daiichi Pharmaceutical; Sanofi-Synthelabo
  • Class Anti-ischaemics; Antiplatelets; Imidazoles; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Thromboxane A2 synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Angina pectoris; Asthma; Diabetic angiopathies; Heart failure; Raynaud's disease

Most Recent Events

  • 19 Dec 2000 Discontinued-Unspecified phase in Heart failure in Europe (Unknown route)
  • 19 Dec 2000 Discontinued-Clinical for Raynaud's disease in Japan (PO)
  • 19 Dec 2000 Discontinued-Unspecified phase in Diabetic angiopathies in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top